2023-02-012024-01-312024-01-31false11139515MAN PHARMA LIMITED2024-10-29iso4217:GBPxbrli:pure111395152023-02-01111395152024-01-31111395152023-02-012024-01-31111395152022-02-01111395152023-01-31111395152022-02-012023-01-3111139515bus:SmallEntities2023-02-012024-01-3111139515bus:AuditExempt-NoAccountantsReport2023-02-012024-01-3111139515bus:FullAccounts2023-02-012024-01-3111139515bus:PrivateLimitedCompanyLtd2023-02-012024-01-3111139515core:WithinOneYear2024-01-3111139515core:AfterOneYear2024-01-3111139515core:WithinOneYear2023-01-3111139515core:AfterOneYear2023-01-3111139515core:ShareCapital2024-01-3111139515core:SharePremium2024-01-3111139515core:RevaluationReserve2024-01-3111139515core:OtherReservesSubtotal2024-01-3111139515core:RetainedEarningsAccumulatedLosses2024-01-3111139515core:ShareCapital2023-01-3111139515core:SharePremium2023-01-3111139515core:RevaluationReserve2023-01-3111139515core:OtherReservesSubtotal2023-01-3111139515core:RetainedEarningsAccumulatedLosses2023-01-3111139515core:LandBuildings2024-01-3111139515core:PlantMachinery2024-01-3111139515core:Vehicles2024-01-3111139515core:FurnitureFittings2024-01-3111139515core:OfficeEquipment2024-01-3111139515core:NetGoodwill2024-01-3111139515core:IntangibleAssetsOtherThanGoodwill2024-01-3111139515core:ListedExchangeTraded2024-01-3111139515core:UnlistedNon-exchangeTraded2024-01-3111139515core:LandBuildings2023-01-3111139515core:PlantMachinery2023-01-3111139515core:Vehicles2023-01-3111139515core:FurnitureFittings2023-01-3111139515core:OfficeEquipment2023-01-3111139515core:NetGoodwill2023-01-3111139515core:IntangibleAssetsOtherThanGoodwill2023-01-3111139515core:ListedExchangeTraded2023-01-3111139515core:UnlistedNon-exchangeTraded2023-01-3111139515core:LandBuildings2023-02-012024-01-3111139515core:PlantMachinery2023-02-012024-01-3111139515core:Vehicles2023-02-012024-01-3111139515core:FurnitureFittings2023-02-012024-01-3111139515core:OfficeEquipment2023-02-012024-01-3111139515core:NetGoodwill2023-02-012024-01-3111139515core:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3111139515core:ListedExchangeTraded2023-02-012024-01-3111139515core:UnlistedNon-exchangeTraded2023-02-012024-01-3111139515core:MoreThanFiveYears2023-02-012024-01-3111139515core:Non-currentFinancialInstruments2024-01-3111139515core:Non-currentFinancialInstruments2023-01-3111139515dpl:CostSales2023-02-012024-01-3111139515dpl:DistributionCosts2023-02-012024-01-3111139515core:LandBuildings2023-02-012024-01-3111139515core:PlantMachinery2023-02-012024-01-3111139515core:Vehicles2023-02-012024-01-3111139515core:FurnitureFittings2023-02-012024-01-3111139515core:OfficeEquipment2023-02-012024-01-3111139515dpl:AdministrativeExpenses2023-02-012024-01-3111139515core:NetGoodwill2023-02-012024-01-3111139515core:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3111139515dpl:GroupUndertakings2023-02-012024-01-3111139515dpl:ParticipatingInterests2023-02-012024-01-3111139515dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-012024-01-3111139515core:ListedExchangeTraded2023-02-012024-01-3111139515dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-012024-01-3111139515core:UnlistedNon-exchangeTraded2023-02-012024-01-3111139515dpl:CostSales2022-02-012023-01-3111139515dpl:DistributionCosts2022-02-012023-01-3111139515core:LandBuildings2022-02-012023-01-3111139515core:PlantMachinery2022-02-012023-01-3111139515core:Vehicles2022-02-012023-01-3111139515core:FurnitureFittings2022-02-012023-01-3111139515core:OfficeEquipment2022-02-012023-01-3111139515dpl:AdministrativeExpenses2022-02-012023-01-3111139515core:NetGoodwill2022-02-012023-01-3111139515core:IntangibleAssetsOtherThanGoodwill2022-02-012023-01-3111139515dpl:GroupUndertakings2022-02-012023-01-3111139515dpl:ParticipatingInterests2022-02-012023-01-3111139515dpl:GroupUndertakingscore:ListedExchangeTraded2022-02-012023-01-3111139515core:ListedExchangeTraded2022-02-012023-01-3111139515dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-02-012023-01-3111139515core:UnlistedNon-exchangeTraded2022-02-012023-01-3111139515core:NetGoodwill2024-01-3111139515core:IntangibleAssetsOtherThanGoodwill2024-01-3111139515core:LandBuildings2024-01-3111139515core:PlantMachinery2024-01-3111139515core:Vehicles2024-01-3111139515core:FurnitureFittings2024-01-3111139515core:OfficeEquipment2024-01-3111139515core:AfterOneYear2024-01-3111139515core:WithinOneYear2024-01-3111139515core:ListedExchangeTraded2024-01-3111139515core:UnlistedNon-exchangeTraded2024-01-3111139515core:ShareCapital2024-01-3111139515core:SharePremium2024-01-3111139515core:RevaluationReserve2024-01-3111139515core:OtherReservesSubtotal2024-01-3111139515core:RetainedEarningsAccumulatedLosses2024-01-3111139515core:NetGoodwill2023-01-3111139515core:IntangibleAssetsOtherThanGoodwill2023-01-3111139515core:LandBuildings2023-01-3111139515core:PlantMachinery2023-01-3111139515core:Vehicles2023-01-3111139515core:FurnitureFittings2023-01-3111139515core:OfficeEquipment2023-01-3111139515core:AfterOneYear2023-01-3111139515core:WithinOneYear2023-01-3111139515core:ListedExchangeTraded2023-01-3111139515core:UnlistedNon-exchangeTraded2023-01-3111139515core:ShareCapital2023-01-3111139515core:SharePremium2023-01-3111139515core:RevaluationReserve2023-01-3111139515core:OtherReservesSubtotal2023-01-3111139515core:RetainedEarningsAccumulatedLosses2023-01-3111139515core:NetGoodwill2022-02-0111139515core:IntangibleAssetsOtherThanGoodwill2022-02-0111139515core:LandBuildings2022-02-0111139515core:PlantMachinery2022-02-0111139515core:Vehicles2022-02-0111139515core:FurnitureFittings2022-02-0111139515core:OfficeEquipment2022-02-0111139515core:AfterOneYear2022-02-0111139515core:WithinOneYear2022-02-0111139515core:ListedExchangeTraded2022-02-0111139515core:UnlistedNon-exchangeTraded2022-02-0111139515core:ShareCapital2022-02-0111139515core:SharePremium2022-02-0111139515core:RevaluationReserve2022-02-0111139515core:OtherReservesSubtotal2022-02-0111139515core:RetainedEarningsAccumulatedLosses2022-02-0111139515core:AfterOneYear2023-02-012024-01-3111139515core:WithinOneYear2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:CostValuation2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3111139515core:Non-currentFinancialInstrumentscore:CostValuation2024-01-3111139515core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:CostValuation2023-01-3111139515core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-3111139515core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-3111139515core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-3111139515core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-3111139515core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-3111139515core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-3111139515bus:Director12023-02-012024-01-31

MAN PHARMA LIMITED

Registered Number
11139515
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2024

MAN PHARMA LIMITED
Company Information
for the year from 1 February 2023 to 31 January 2024

Director

Issac, Abdullah

Registered Address

472 Greenford Road
Greenford
UB6 8SQ

Registered Number

11139515 (England and Wales)
MAN PHARMA LIMITED
Balance Sheet as at
31 January 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets34,3485,435
4,3485,435
Current assets
Debtors442,64438,123
Cash at bank and on hand126,149127,016
168,793165,139
Creditors amounts falling due within one year5(13,772)(17,888)
Net current assets (liabilities)155,021147,251
Total assets less current liabilities159,369152,686
Net assets159,369152,686
Capital and reserves
Called up share capital11
Profit and loss account159,368152,685
Shareholders' funds159,369152,686
The financial statements were approved and authorised for issue by the Director on 29 October 2024, and are signed on its behalf by:
Issac, Abdullah
Director
Registered Company No. 11139515
MAN PHARMA LIMITED
Notes to the Financial Statements
for the year ended 31 January 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Vehicles20
2.Average number of employees

20242023
Average number of employees during the year11
3.Tangible fixed assets

Vehicles

Total

££
Cost or valuation
At 01 February 2316,58716,587
At 31 January 2416,58716,587
Depreciation and impairment
At 01 February 2311,15211,152
Charge for year1,0871,087
At 31 January 2412,23912,239
Net book value
At 31 January 244,3484,348
At 31 January 235,4355,435
4.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables9,478-
Other debtors33,166-
Prepayments and accrued income-38,123
Total42,64438,123
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables16823
Taxation and social security12,13116,120
Other creditors1,625696
Accrued liabilities and deferred income-249
Total13,77217,888
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.